A discussion on the clinical factors that put patients at risk of having relapsed DLBCL.
Updated Data Show Efficacy of Tafasitamab/Lenalidomide in R/R DLBCL
November 28th 2023In the first article of a 2-part series, Hayder Saeed, MD, discusses the 5-year follow up data from the L-MIND study, which shows the continuing efficacy of tafasitamab and lenalidomide for patients with relapsed/refractory diffuse large B-cell lymphoma.
Read More
Immunotherapy in Addition to R-CHOP Improves a SOC in DLBCL
November 15th 2023In the first article of a 2-part series, Herbert A. Eradat, MD, discusses the research down that led to the use of the immunotherapy polatuzumab vedotin in combination with chemotherapy for patients with diffuse large B-cell lymphoma.
Read More